|
The National Agency for Research and Innovation (ANII) of Uruguay has granted Xeptiva Therapeutics new funding to cover the costs associated with the national patent phases of its products in LATAM, Asia, and Europe. This request was approved by ANII in June 2024. The project, titled “Support for Patent Registration of Inventions and Utility Models”, includes six initiatives that meet this objective and seek to strengthen the company’s intellectual property protection in key markets. These patent phases are essential to ensure that Xeptiva’s developments are protected in various regions allowing the company to maximize its commercial potential and expand its international presence. |
The funding provided by ANII covers 80% of the total costs associated with these projects, while the remaining 20% will be contributed by Xeptiva. The duration of each project is 12 months.
This government grant represents an essential pillar for Xeptiva, as it will facilitate the acquisition of patents in strategic markets, which in turn will enhance its research and development capabilities.
This government grant represents an essential pillar for Xeptiva, as it will facilitate the acquisition of patents in strategic markets, which in turn will enhance its research and development capabilities.